Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
botulinum toxin type A (Chumakov Federal Scientific Center)
- Development stage
- Phase 3
- Lead developer
- Chumakov Federal Scientific Center
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Miotox is a liquid formulation of botulinum toxin type A developed by the Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products in Russia. Unlike many other botulinum toxin products that require reconstitution from a vacuum-dried powder, Miotox is provided as a ready-to-use stable liquid. It acts as a neuromuscular blocking agent by inhibiting the release of acetylcholine at the neuromuscular junction through the cleavage of SNAP-25, leading to localized muscle relaxation. Miotox is primarily indicated for the treatment of focal spasticity, including dynamic foot deformity in children with cerebral palsy, and is also widely used in aesthetic medicine for the correction of facial wrinkles.
- Brand names
- MiotoxМиотокс
- Other names
- botulinum toxin type Aliquid botulinum toxin type A
02
Targets
SNAP25 (Synaptosome-associated protein 25)
Beyond the preview
Go deeper on botulinum toxin type A (Chumakov Federal Scientific Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on botulinum toxin type A (Chumakov Federal Scientific Center).